Spots Global Cancer Trial Database for kras p.g12c
Every month we try and update this database with for kras p.g12c cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy | NCT05398094 | Non-small Cell ... KRAS P.G12C | Sotorasib | 18 Years - | Fundación GECP | |
| Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | NCT05251038 | Pancreatic Canc... Unresectable Pa... Metastatic Panc... KRAS P.G12C | Sotorasib Liposomal Irino... 5 Fluorouracil ... Leucovorin (LV) Gemcitabine (GE... Nab paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | NCT05288205 | KRAS P.G12C Non-small Cell ... Colorectal Canc... Pancreatic Duct... | JAB-21822 JAB-3312 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | NCT05631249 | KRAS P.G12C Non Small Cell ... | Sotorasib 120Mg... | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status | NCT05673187 | NSCLC Stage IV KRAS P.G12C | Adagrasib | 18 Years - | ETOP IBCSG Partners Foundation | |
| Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | NCT05631249 | KRAS P.G12C Non Small Cell ... | Sotorasib 120Mg... | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| RW Efficacy of Sotorasib in KRAS G12C-mutated Metastatic NSCLC | NCT05273047 | Nsclc KRAS P.G12C | 18 Years - 90 Years | Intergroupe Francophone de Cancerologie Thoracique | ||
| A Study of JAB-21822 in Patients With KRAS p.G12C Mutated Pancreatic Cancer | NCT06008288 | KRAS P.G12C Pancreatic Canc... | JAB-21822 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | NCT05920356 | Non-Small Cell ... | Sotorasib Pembrolizumab | 18 Years - 100 Years | Amgen | |
| Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer | NCT05251038 | Pancreatic Canc... Unresectable Pa... Metastatic Panc... KRAS P.G12C | Sotorasib Liposomal Irino... 5 Fluorouracil ... Leucovorin (LV) Gemcitabine (GE... Nab paclitaxel | 18 Years - | Hoosier Cancer Research Network | |
| Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | NCT05288205 | KRAS P.G12C Non-small Cell ... Colorectal Canc... Pancreatic Duct... | JAB-21822 JAB-3312 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Studying Pathways of Resistance in KRAS-driven Cancers | NCT05272423 | KRAS P.G12C | FoundationOne® ... | 18 Years - | Addario Lung Cancer Medical Institute | |
| A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | NCT05410145 | KRAS P.G12C | D3S-001 Pembrolizumab Cisplatin Carboplatin Pemetrexed Cetuximab | 18 Years - | D3 Bio (Wuxi) Co., Ltd |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
